Drug Type Small molecule drug |
Synonyms Flurbiprofen sodium (USP), 氟吡洛芬钠, AGN-101289 + [3] |
Target |
Action inhibitors |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (31 Dec 1986), |
Regulation- |
Molecular FormulaC15H13FNaO2 |
InChIKeyCGCMNXTUJNJYIY-UHFFFAOYSA-N |
CAS Registry56767-76-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02290 | Flurbiprofen Sodium | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Ankylosing Spondylitis | China | 01 Jan 1998 | |
| Osteoarthritis | China | 01 Jan 1998 | |
| Pain | China | 01 Jan 1998 | |
| Rheumatoid Arthritis | China | 01 Jan 1998 | |
| Miosis | United States | 31 Dec 1986 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoarthritis, Knee | Phase 3 | China | 31 Mar 2020 | |
| Osteoarthritis, Knee | Phase 3 | China | 31 Mar 2020 |





